Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Screened 2026-09-17 · the tape above runs as of 15:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Exelixis Inc holds its Accumulation at $58.49. Consolidating, no directional conviction, held for 5 days.
As held on the ledger · 2026-09-17
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 5 days
Price at the screen
$58.49
Valuation
18.39 trailing · 13.73 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.42
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
6.08%
Below 33%
Interest-bearing debt is just 6.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
20.27%
Below 33%
Cash held in interest-bearing accounts and securities is 20.3% of assets, under the one-third limit.
Pass
Receivables
27.05%
Below 49%
Money owed to the company is 27.0% of assets, under the 49% limit.
Pass
Revenue purity
2.98%
Below 5%
Only 3.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-17 screen. The gold marker is the market price at the same screen. A 12.2% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits −10% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
One cancer drug carries a whole biotech
A single approved pill for tough kidney cancers keeps the cash flowing at Exelixis. The business posts a 35 percent profit margin and 41 percent return on equity while revenue edges up 10 percent a year. Forward earnings sit at just 14 times and the ethical screen clears without issue, so the numbers look solid on paper.
Yet the narrow moat leaves little room for error if competition arrives or regulators shift the goalposts. Our own fair value sits only 11 percent above the current price, the opportunity rating stays at none, and fifteen analysts cluster around a $50 target that sits below where the shares trade today.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EXEL trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-28Markup$50.61-9.5%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49.
2026-07-28Markup$55.92+5.3%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49.
2026-07-18Markup$53.13+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (16 analysts) rates it buy, with a mean price target of $49.
2026-07-03Markup$53.13+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$53.13Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
